Absence of tissue transglutaminase reduces amyloid‐beta pathology in APP23 mice

AIMS: Alzheimer's disease (AD) is characterised by amyloid‐beta (Aβ) aggregates in the brain. Targeting Aβ aggregates is a major approach for AD therapies, although attempts have had little to no success so far. A novel treatment option is to focus on blocking the actual formation of Aβ multime...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilhelmus, Micha M. M., Chouchane, Osoul, Loos, Maarten, Jongenelen, Cornelis A. M., Brevé, John J. P., Jonker, Allert, Bol, John G. J. M., Smit, August B., Drukarch, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304226/
https://www.ncbi.nlm.nih.gov/pubmed/35141929
http://dx.doi.org/10.1111/nan.12796

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9304226/
https://www.ncbi.nlm.nih.gov/pubmed/35141929
http://dx.doi.org/10.1111/nan.12796

Ejemplares similares